One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.

Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Järvinen H, Diamant M, Taskinen MR

Atherosclerosis29 Apr 2010Cited by 114 (Europe PMC)

PMID20494360DOI10.1016/j.atherosclerosis.2010.04.024PepBankPUB-20494360

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial glucose excursions from pretreatment values.
In plain wordsIn patients with diabetes, blood sugar rises after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial glucose excursions
Study
n = 30
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436001
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial triglyceride excursions from pretreatment values.
In plain wordsIn patients with diabetes, triglyceride rises after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial triglyceride excursions
Study
n = 30
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436002
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial apo-B48 excursions from pretreatment values.
In plain wordsIn patients with diabetes, apo-B48 rises after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial apo-B48 excursions
Study
n = 30
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436003
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial calculated VLDL-C excursions from pretreatment values.
In plain wordsIn patients with diabetes, calculated VLDL cholesterol rises after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial calculated VLDL-C excursions
Study
n = 30
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436004
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial free fatty acid excursions from pretreatment values.
In plain wordsIn patients with diabetes, free fatty acid excursions after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial FFA excursions
Study
n = 30
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436005
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, exenatide significantly reduced prandial MDA excursions from pretreatment values.
In plain wordsIn patients with diabetes, MDA excursions after meals decreased during exenatide treatment compared with pretreatment values.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePrandial MDA excursions
Study
n = 30
Outcome group
Oxidative stress · Whole body
Studied dose
Dose not stated · 51 weeksAs given in this study (human).
Source sentences
Summary
51-Week exenatide treatment resulted in a significant reduction of prandial glucose, triglycerides, apo-B48, calculated VLDL-C, FFA and MDA excursions whereas Insulin Glargine predominantly reduced fasting glucose, FFA and MDA.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
Report a problemFND-2049436006

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, all postprandial measures returned to pretreatment values after cessation of either exenatide or insulin glargine.
In plain wordsIn patients with diabetes, all meal-related measures returned to starting values after either exenatide or insulin glargine treatment stopped.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePostprandial measures after treatment cessation
Study
n: not reported in source
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
All postprandial measures returned to pre-treatment values in both groups after 5-week cessation of study treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-nine metformin-treated patients with type 2 diabetes were randomised (using apermuted block randomisation scheme stratified by site and baseline HbA(1c) stratum (8.5%) of which 60 completed (exenatide n=30; Insulin Glargine n=30) the pre-treatment and on-drug meal test.
Summary · context
Postprandial glucose, lipids and lipoproteins, and oxidative stress markers were studied at week -1, 51, and after a 5-week off-drug period following a breakfast and lunch mixed-meal containing 50 g fat, 75 g carbohydrates, and 35 g protein.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2049436008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00097500

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

AstraZenecan = 69Sept 2004 to Dec 2009

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 7 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.